CYP450 questions are the classic “I knew this once” traps: the stem gives you one clue (a new med, a lab abnormality, a pregnancy scare, a breakthrough seizure), and the answer choices are packed with plausible enzyme names that all feel kind of the same at 2 a.m. The trick is to stop treating these as memorization-only and start treating them like predictable pharmacokinetic logic problems—and then use the distractors to prove you actually understand the pattern.
Tag: Pharmacology > General Principles
The Clinical Vignette (Q-bank style)
A 28-year-old woman with epilepsy has been seizure-free for 3 years on lamotrigine and a combined oral contraceptive pill (ethinyl estradiol + progestin). She recently started carbamazepine after a breakthrough seizure. Two months later, she reports new irregular bleeding and is concerned about pregnancy. A urine pregnancy test is negative.
Which of the following best explains her new symptoms?
A. Carbamazepine inhibits CYP3A4, increasing estrogen metabolism
B. Carbamazepine induces CYP3A4, increasing estrogen clearance
C. Ethinyl estradiol induces CYP2C9, decreasing carbamazepine levels
D. Lamotrigine inhibits UDP-glucuronosyltransferase, increasing estrogen levels
E. Progestins inhibit P-glycoprotein, decreasing carbamazepine clearance
Step-by-Step: What’s happening physiologically?
This is a drug–drug interaction question with a real-world clinical consequence: contraceptive failure / breakthrough bleeding.
- Carbamazepine is a classic hepatic enzyme inducer, especially CYP3A4 (and others).
- Many oral contraceptive components (especially ethinyl estradiol) are metabolized by CYP3A4.
- Inducing CYP3A4 → faster metabolism of estrogen/progestin → lower hormone levels → breakthrough bleeding and increased risk of unintended pregnancy.
High-yield rule:
Inducers decrease substrate levels (by increasing metabolism).
Inhibitors increase substrate levels (by decreasing metabolism).
Correct Answer: B. Carbamazepine induces CYP3A4, increasing estrogen clearance
Why it’s correct
Carbamazepine is a CYP450 inducer (think: “turns on the liver”). Enzyme induction:
- takes days to weeks to fully develop (requires increased transcription/translation)
- causes decreased plasma levels of drugs metabolized by that enzyme
So here:
- Carbamazepine induces CYP3A4
- CYP3A4 metabolizes ethinyl estradiol (and many progestins)
- Hormone levels fall → irregular bleeding and decreased contraceptive efficacy
USMLE high-yield counseling point
Patients starting enzyme-inducing antiepileptics should be advised to use backup contraception or switch to methods less dependent on CYP metabolism (e.g., copper IUD; some progestin-only methods are also affected—test writers vary, but the safe exam move is “backup needed”).
Now, the real score boost: Why every distractor is wrong (and what it’s trying to teach)
A. Carbamazepine inhibits CYP3A4, increasing estrogen metabolism
This choice is internally contradictory and conceptually wrong in two ways:
- Inhibition does NOT increase metabolism; it decreases metabolism.
- Carbamazepine is an inducer, not an inhibitor.
Exam reflex: If you see “inhibits CYP → increasing metabolism,” that’s a red flag. Inhibiting the enzyme means the substrate sticks around longer.
C. Ethinyl estradiol induces CYP2C9, decreasing carbamazepine levels
This distractor is testing whether you can:
- keep straight who affects whom, and
- remember that oral contraceptives are not the classic “big inducer” culprits.
Problems:
- Ethinyl estradiol is not a clinically important CYP2C9 inducer in the way Step expects you to use “inducer logic.”
- Carbamazepine is primarily metabolized by CYP3A4 (plus it’s a notorious autoinducer), not mainly “taken down” by estrogen-induced CYP2C9.
- The clinical presentation is low estrogen effect (breakthrough bleeding), not loss of seizure control due to low carbamazepine.
High-yield anchor: When contraception fails after starting a new med, suspect enzyme induction by the new medication, not the OCP changing the anticonvulsant.
D. Lamotrigine inhibits UDP-glucuronosyltransferase, increasing estrogen levels
This option is trying to bait you with “lamotrigine interaction” facts, but it flips the direction and the enzyme.
Reality:
- Lamotrigine is primarily cleared by glucuronidation (UGT enzymes).
- Ethinyl estradiol can induce UGT, which can decrease lamotrigine levels → potential loss of seizure control.
- Lamotrigine is not a meaningful UGT inhibitor that would raise estrogen levels.
USMLE pearl (commonly tested):
- OCPs ↓ lamotrigine levels (via UGT induction)
- Enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital) ↓ OCP efficacy (via CYP induction)
The vignette gives you bleeding/contraceptive issue, not worsening seizures—so the intended interaction is the AED → OCP direction.
E. Progestins inhibit P-glycoprotein, decreasing carbamazepine clearance
This is a transporter decoy (P-gp) to see if you overgeneralize.
Why it’s wrong:
- The classic, high-yield mechanism for OCP failure with carbamazepine is CYP3A4 induction, not P-gp inhibition.
- P-glycoprotein effects matter for certain drugs (e.g., digoxin) and tissues (gut, BBB), but it’s not the central explanation for this clinical picture.
- Also note the mismatch: the stem screams low hormone effect, but this answer describes increased carbamazepine levels (would more likely cause toxicity like diplopia, ataxia, nystagmus).
Mini-Table: Inducers vs Inhibitors (Step-friendly)
| Category | What happens to enzyme activity? | What happens to substrate drug level? | Onset/offset | Classic consequence |
|---|---|---|---|---|
| Inducer | ↑ | ↓ | Slow (days–weeks) | Therapeutic failure (e.g., OCP failure, transplant rejection, breakthrough seizures) |
| Inhibitor | ↓ | ↑ | Fast (hours–days) | Toxicity (e.g., bleeding on warfarin, rhabdo with statins) |
High-Yield CYP450 and “Non-CYP” Players You Should Know
Common CYP Inducers (think “PS PORCS” + a few)
High-yield set:
- Phenytoin
- Smoking (induces CYP1A2)
- Phenobarbital
- Oxcarbazepine (often treated like an inducer on exams)
- Rifampin (big one)
- Carbamazepine
- St. John’s wort
Clinical pattern: Inducers lower levels of things like warfarin, OCPs, antiretrovirals, calcineurin inhibitors.
Common CYP Inhibitors (high-yield)
- Cimetidine
- Macrolides (esp. clarithromycin, erythromycin)
- Azole antifungals (ketoconazole, itraconazole, fluconazole—varies by strength)
- Protease inhibitors (ritonavir strongest; used as a “booster”)
- Amiodarone
- Isoniazid
- Grapefruit juice (intestinal CYP3A4 inhibition)
Clinical pattern: Inhibitors raise levels of substrates → toxicity (e.g., warfarin bleeding, statin rhabdo, QT risk).
Non-CYP metabolism that shows up a lot
- UGT (glucuronidation): lamotrigine, bilirubin conjugation
- NAT acetylation: isoniazid (slow acetylators → neuropathy, lupus-like syndrome)
- Pseudocholinesterase: succinylcholine (prolonged paralysis in deficiency)
“Answer Choice Triage” Strategy for CYP Questions
When you’re stuck between two plausible options, do this fast:
-
Identify the victim drug (substrate) from the symptoms
- Bleeding + pregnancy scare → OCP levels likely down
- Sedation/ataxia → anticonvulsant toxicity likely up
- Bleeding on warfarin → warfarin level likely up
-
Match direction with mechanism
- Induction → substrate down
- Inhibition → substrate up
-
Check time course
- Symptoms appearing weeks after starting a drug favors induction
- Symptoms appearing within 1–2 days favors inhibition
-
Don’t get baited by fancy transporters unless the stem points there
- Most Step-style interactions are still CYP3A4 or UGT classics.
Key Takeaways (what you should remember on test day)
- Carbamazepine induces CYP3A4 → decreases OCP levels → breakthrough bleeding and contraceptive failure risk.
- Inducers = slow onset, therapeutic failure. Inhibitors = fast onset, toxicity.
- Lamotrigine is a UGT-cleared drug: OCPs can lower lamotrigine levels (reverse direction from this vignette).
- If an answer choice says “inhibits CYP → increases metabolism,” it’s almost certainly wrong.